로고
About us
Company overview
History
Leadership
Business Strategy
Contact us
Core Technology
Antibody Discovery
Bispecific Antibody
Platform
Development Capability
Pipeline
Overview
IMB-101/102
IMB-201
IMB-301
IMB-401
Media Room
Notice
News
Gallery
Careers
Culture
Recruiting Information
언어선택
ENG
KOR
ENG
전체메뉴
About us
Company overview
History
Leadership
Business Strategy
Contact us
Core Technology
Antibody Discovery
Bispecific Antibody
Platform
Development Capability
Pipeline
Overview
IMB-101/102
IMB-201
IMB-301
IMB-401
Media Room
Notice
News
Gallery
Careers
Culture
Recruiting Information
History
Innovative Medicines based on
ImmunoModulatory Biologics
About us
About us
Core Technology
Pipeline
Media Room
Careers
History
Company overview
History
Leadership
Business Strategy
Contact us
Global biotechnology company
that benefits the world
2021
08
Completion of 13 Bil. KRW Series A Funding by KB, Atinum, Partners, IMM and Timewise investment firms
04
Completion of the trademark application
03
Approval of the LMO facility
03
The 1st annual shareholder meeting
02
Certification of the venture company
01
Completion of 4 Bil. KRW Seed Funding led by KB investment and Atinum investment
2020
12
Certification of the company-affiliated research institute
11
Relocation of the HQ and the research institute to Gwanggyo Central Biz Tower
11
Worldwide exclusive in-licensing agreement for OXTIMA(IMB-101) with HK inno.N
10
Patent application for the IMB platform technology
09
Temporary research institute established at Gyeonggi Bio Center
08
Establishment of IMBiologics Inc.
President(CEO) : Gyongsik Ha
260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea